Department of Cell Biology and Neuroscience, University of California at Riverside, Riverside, California 92521, USA.
Cytotherapy. 2009;11(7):815-24. doi: 10.3109/14653240903180092.
Multipotent human neural stem cells (hNSC) have traditionally been isolated directly from the central nervous system (CNS). To date, as a therapeutic tool in the treatment of neurologic disorders, the most promising results have been obtained using hNSC isolated directly from the human fetal neuroectoderm. The propagation ability of such tissue-derived hNSC is often limited, however, making it difficult to establish a large-scale culture. Following engraftment, these hNSC often show low efficiency in generating the desired neuronal cells necessary for reconstruction of the damaged host milieu and, as a result, have failed to give satisfactory results in clinical trials so far. Alternatively, human embryonic stem cells (hESC) offer a pluripotent reservoir for in vitro derivation of a rich spectrum of well-characterized neural-lineage committed stem/progenitor/precursor cells that can, theoretically, be picked at precisely their safest and most efficacious state of plasticity to meet a given clinical challenge. However, the need for 'foreign' biologic additives and multilineage differentiation inclination may make direct use of such cell-derived hNSC in patients problematic. The hNSC, when derived from pluripotent cells under protocols presently employed in the field, tend to display not only a low efficiency in neuronal differentiation, but also an inclination for phenotypic heterogeneity and instability and, hence, increased risk of tumorigenesis following engraftment. For hNSC derived in vitro to be used safely in therapeutic paradigms, it requires conversion of human pluripotent cells uniformly to cells that are restricted to the neural lineage in need of repair. Developing strategies for direct induction of human pluripotent cells exclusively into neural-committed progenies at a broad range of developmental stages will allow a large supply of optimal therapeutic hNSC tailor-made for safe and effective treatment of particular neurologic diseases and injuries in patients.
多能人神经干细胞(hNSC)传统上是直接从中枢神经系统(CNS)中分离出来的。迄今为止,作为治疗神经疾病的治疗工具,最有前途的结果是使用直接从人胎儿神经外胚层分离的 hNSC 获得的。然而,这种组织来源的 hNSC 的增殖能力常常受到限制,因此难以建立大规模培养。移植后,这些 hNSC 通常在产生所需的神经元细胞方面效率低下,这些神经元细胞对于重建受损宿主环境是必要的,因此迄今为止,在临床试验中并未取得令人满意的结果。或者,人胚胎干细胞(hESC)为体外衍生丰富的具有特征的神经谱系定向干细胞/祖细胞/前体细胞提供了多能库,这些细胞理论上可以在最安全和最有效的可塑性状态下被挑选出来,以满足特定的临床挑战。然而,对于“外来”生物添加剂的需求和多谱系分化倾向可能会使直接使用此类细胞衍生的 hNSC 在患者中出现问题。当根据目前在该领域中使用的方案从多能细胞中衍生出 hNSC 时,不仅神经元分化效率低,而且还倾向于表现出表型异质性和不稳定性,因此在移植后增加了致瘤的风险。为了使体外衍生的 hNSC 能够安全地用于治疗方案,需要将人多能细胞统一转化为仅需要修复的神经谱系中的细胞。开发直接将人多能细胞专一地诱导为广泛发育阶段的神经定向祖细胞的策略,将允许大量供应针对特定神经疾病和损伤的最佳治疗性 hNSC,以安全有效地治疗患者。